Biocon reports Q4FY26, FY26 consolidated results; profit before exceptionals down YoY
Biocon · Pharmaceuticals & Biotechnology
Key highlights
- Q4FY26 total income ₹4,569 crore, up 10% YoY excluding one-time generic lenalidomide sales in Q4FY25; reported Q4FY25 total income was ₹4,454 crore
- Q4FY26 net profit before exceptional items ₹179 crore vs ₹333 crore in Q4FY25 reported; the 64% rise excludes one-time lenalidomide sales
- FY26 net profit before exceptional items ₹436 crore vs ₹981 crore in FY25 reported; the 323% rise is adjusted for lenalidomide sales and BFI divestment gain
Why it's rated major development: the year-on-year change is 46% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Biocon
- Order winNotableBiocon secures 10-year Pertuzumab supply contract in Brazil under PDP program
- Acquisition / mergerMajor developmentBiocon Limited board approves Q4 results, dividend, auditor change and BBL share swap
- Fundraise / allotmentNotableBiocon: board okays share swap for ~2% of BBL, Q4 results, Re. 0.50 dividend
- Dividend / buyback / bonusMajor developmentBiocon board approves share swap to acquire remaining BBL stake via preferential issue
- Acquisition / mergerNotableBiocon Limited announces acquisition of Biocon Biologics shares via preferential issue
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.